• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

作者信息

Tannock Ian F, Pond Gregory R, Booth Christopher M

机构信息

Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

出版信息

JAMA Oncol. 2022 May 1;8(5):679-680. doi: 10.1001/jamaoncol.2021.8206.

DOI:10.1001/jamaoncol.2021.8206
PMID:35266952
Abstract
摘要

相似文献

1
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.癌症药物试验中的偏倚评估——将无进展生存期用作主要终点如何会产生误导。
JAMA Oncol. 2022 May 1;8(5):679-680. doi: 10.1001/jamaoncol.2021.8206.
2
Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.无进展生存期获益：药物注册的可靠主要终点，可加速患者获得急需治疗
J Clin Oncol. 2024 Mar 10;42(8):973-974. doi: 10.1200/JCO.23.02259. Epub 2024 Jan 30.
3
Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.无进展生存期作为实体瘤的一个终点——来自临床试验和临床实践的观点
Eur J Cancer. 2014 Sep;50(13):2303-8. doi: 10.1016/j.ejca.2014.05.024. Epub 2014 Jun 25.
4
Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.无进展生存期：作为金标准的总生存期获益和加速药物研发。
Cancer J. 2009 Sep-Oct;15(5):386-94. doi: 10.1097/PPO.0b013e3181b9c5ec.
5
Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.无进展生存期与总生存期作为抗癌药物试验的主要终点：疾病进展后治疗的影响日益显著
Curr Oncol Rep. 2009 Jan;11(1):1-2. doi: 10.1007/s11912-009-0001-y.
6
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.无病生存作为实体瘤治疗的终点——来自临床试验和临床实践的观点
Eur J Cancer. 2014 Sep;50(13):2298-302. doi: 10.1016/j.ejca.2014.05.016. Epub 2014 Jun 12.
7
Progression-free survival in oncology: Caveat emptor!肿瘤学中的无进展生存期：谨慎购买！
Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):240-244. doi: 10.1111/bcpt.13168. Epub 2018 Dec 12.
8
Inappropriate use of progression-free survival in cancer drug approvals.癌症药物批准中无进展生存期的不当使用。
BMJ. 2020 Mar 10;368:m770. doi: 10.1136/bmj.m770.
9
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.癌症药物试验中的总生存期作为现实世界中总生存期的新替代终点
JAMA Oncol. 2017 Jul 1;3(7):889-890. doi: 10.1001/jamaoncol.2016.5296.
10
Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.总生存期：仍是金标准：为何总生存期仍是癌症临床试验的明确终点。
Cancer J. 2009 Sep-Oct;15(5):401-5. doi: 10.1097/PPO.0b013e3181bdc2e0.

引用本文的文献

1
Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized C MRI-A Correlative Study with Clinical Outcomes.使用全腹和盆腔超极化碳磁共振成像对晚期前列腺癌代谢进行多变量分析框架——与临床结果的相关性研究
Cancers (Basel). 2025 Jul 1;17(13):2211. doi: 10.3390/cancers17132211.
2
How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.作为一类推荐方案添加塞利尼索/硼替佐米/地塞米松如何可能会降低治疗效果。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf122.
3
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas.
定义生物学和临床合理性：跨治疗领域生存外推中方案化评估的DICSA框架。
Pharmacoeconomics. 2025 Mar 29. doi: 10.1007/s40273-025-01485-0.
4
Putting Patients First: Pragmatic Trials in Gynecologic Oncology.将患者放在首位：妇科肿瘤学中的务实试验
Curr Oncol. 2025 Feb 27;32(3):139. doi: 10.3390/curroncol32030139.
5
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials.一线PD-1/PD-L1抑制剂联合化疗治疗晚期鳞状非小细胞肺癌的比较结果：一项随机临床试验的系统评价和网状Meta分析
Transl Lung Cancer Res. 2025 Feb 28;14(2):563-574. doi: 10.21037/tlcr-2025-83. Epub 2025 Feb 27.
6
A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer.一项关于晚期非小细胞肺癌免疫联合治疗双重预测标志物的队列研究。
Biomark Insights. 2025 Feb 14;20:11772719251319641. doi: 10.1177/11772719251319641. eCollection 2025.
7
Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward.肿瘤学中替代终点的常见问题——机遇、陷阱与未来方向
EClinicalMedicine. 2024 Sep 13;76:102824. doi: 10.1016/j.eclinm.2024.102824. eCollection 2024 Oct.
8
Changes in essential cancer medicines and association with cancer outcomes: an observational study of 158 countries.基本癌症药物的变化及其与癌症结局的关联：一项对158个国家的观察性研究
BMC Cancer. 2024 Dec 18;24(1):1526. doi: 10.1186/s12885-024-13247-w.
9
Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy.量化形态学变化，作为检查点抑制治疗后不可切除原发性肝癌标准反应标准的替代方法。
Radiol Med. 2025 Feb;130(2):226-234. doi: 10.1007/s11547-024-01937-1. Epub 2024 Dec 10.
10
Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit.镥-177 PSMA-617注册研究中的设计问题使实验臂的结果产生偏差，这反映出现代肿瘤学试验与真正的患者获益之间的不一致性日益增加。
BJC Rep. 2024 Jun 24;2(1):45. doi: 10.1038/s44276-024-00065-7.